Context

BioNTech is a German one stop shop immuno-oncology company with a full spectrum of technologies to tackle cancer, which differentiates it from other mRNA and immuno-oncology companies.

The company’s mRNA-based platform serves as a foundation on which it can build multiple treatment modalities, including cancer vaccines FixVac, based on a fixed combination of shared cancer antigens, and iNeST for patient-specific cancer antigen therapy.

In March 2020 the company leveraged its mRNA platform and its infectious diseases partnership with Pfizer by expanding its pipeline to Covid-19, and in this context signed an additional partnership with Fosun. In July 2020, BioNTech and Pfizer signed multiple supply agreements for Covid 19 vaccine with the UK and US governments.

BioNTech has developed industry-leading collaborations across all pipeline with Pfizer, Fosun Genmab, Genentech, Sanofi…

BioNTech_website_tombstone

About BioNTech

Biopharmaceutical New Technologies (BioNTech) is a next-generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Genevant, Fosun Pharma and Pfizer.

Discover BioNTech

Pierre Kiecolt-Wahl

Equity Capital Markets

Pierre Kiecolt-Wahl photo

Sandrine Cailleteau

Investment Banking

Sandrine Cailleteau photo

Gregoire Angleys

Investment Banking

Gregoire Angleys photo

Mickael Dubourd

Investment Banking

Mickael Dubourd photo

Pierre Sertour

Equity Capital Markets

Pierre Sertour photo

Deal Team

Should you want to know more about this transaction, you can contact one of the team members above

Privacy Preference Center